Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT O	F CHANGES IN	BENEFICIAL	OWNERSHIP

OMB API	PROVAL
OMB Number:	3235-0287
Estimated average	burden
houre per response	۰. ۵۰

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Grunberg Gregory</u>						2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [ KALA ]									ionship of Reportin all applicable) Director		on(s) to Issu 10% Ow			
(Last)	•	irst) MACEUTICALS	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/05/2019									(give title		Other (s below)	pecify		
490 ARSENAL WAY, SUITE 120				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	ΓOWN M	1A	02472											X Form f	iled by Mor		orting Persor One Repor			
(City)	(S	State)	(Zip)																	
		Tak	le I - Noi	ո-Deri	vativ	e Se	curities	s Ac	quired, D	ispo	sed o	f, or Be	neficial	ly Owned						
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				action 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)  5)				Benefici Owned F	es For ally (D) following (I) (	Form (D) or	rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership						
								Code V	' A	Amount	(A) or (D)	Price		nsaction(s) str. 3 and 4)			(Instr. 4)			
									uired, Dis , options					Owned			·			
Derivative Conversion Date Executive Or Exercise (Month/Day/Year) if an		3A. Deeme Execution if any (Month/Day	Date, Transaction Code (Instr.			n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisable	Expi Date	iration e	Title	Amount or Number of Shares							
Stock Option (right to buy)	\$5.35	06/05/2019			A		21,000		(1)	06/0	04/2029	Common Stock	21,000	\$0	21,000	)	D			

## **Explanation of Responses:**

1. This option was granted on June 5, 2019 and vests with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter.

/s/ Mary Reumuth, Attorney-in-06/07/2019 **Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.